Is There Any Hope Left for Sage Therapeutics?

Mid-cap biotech Sage Therapeutics (NASDAQ:SAGE) has been a lackluster performer lately. Shares have declined by nearly 80% over the past 12 months. Meanwhile, the S&P 500 is up over 12% in the same period.

Will the company be able to recover from its setbacks and deliver promising pipeline results for shareholders? Let's find out.